Cancer is one of the leading causes of death worldwide causing approximately 1 in every 7 deaths.
In 2012, 8.2 million people died of the disease with 14 million new cases recorded in that year (WHO Figures).
In 2030, the number of new cancer cases is projected to be >22 million (50-70% increase) due to the increasing population age and size.
Cancer immunotherapy (active and passive) aims to harness the body’s own immune system in the fight against tumour progression. In the past decade, this strategy has become the most promising in the search for novel cancer therapies.
Recent breakthroughs include either tumour specific/bi-specific monoclonal antibodies (mAbs), checkpoint inhibitors, adoptive cell therapy and therapeutic cancer vaccines (peptides, dendritic cells, allogenic cells, autologous cells, oncolytic viruses).
For the latter group, Dendreon’s Provenge® (Sipuleucel-T) was the first therapeutic vaccine approved for any cancer.
This MarketVIEW product consists of a detailed Executive presentation (~100 slides) and MS-Excel work book summarizing current approaches in cancer immunotherapy
with an in-depth focus on the therapeutic cancer vaccine category. Included is an analysis of over 300 verified cancer vaccine programs (Phase I-III) delineated by sponsor,
sponsor type, mechanism, tumour type, results, and other relevant fields. Detailed case studies are presented for the identified late stage (Phase III) industry sponsored programs
e.g. PROSTVAC® Bavarian Nordic with presentation of clinical trial data relevant to the Provenge® (Sipuleucel-T) reference for FDA approval. This analysis is recommended to any client wishing to understand quickly the commercial landscape of the therapeutic cancer vaccine field within the overview dynamic of cancer immunotherapy.
THIS PRODUCT IS A SUMMARY PRESENTATION + ONE WORKBOOK